• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cullinan Therapeutics Inc.

    4/28/26 6:54:21 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEM alert in real time by email
    DEFA14A 1 2025_defa14a_filing.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    Information Required in Proxy Statement

    Schedule 14A Information

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

    CULLINAN THERAPEUTICS, INC.

    (Name of Registrant as Specified in its Charter)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

     

    ☐

    Fee paid previously with preliminary materials.

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

    img82967796_0.jpg

    Cullinan Therapeutics Your Vote Counts! CULLINAN THERAPEUTICS, INC. CULLINAN THERAPEUTICS, INC. ONE MAIN STREET SUITE 1350 CAMBRIDGE, MA 02142 V91728-P50928 2026 Annual Meeting Vote by June 15, 2026 11:59 PM ET You invested in CULLINAN THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 16, 2026 at 10:00 a.m., Eastern Time. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 2, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 16, 2026 10:00 a.m., Eastern Time Virtually at: www.virtualshareholdermeeting.com/CGEM2026 *Please check the meeting materials for any special requirements for meeting attendance.


     

    img82967796_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Nominees: 01. Nadim Ahmed 02 Stephen Webster 2. Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026. 3. Proposal to vote, on an advisory basis, to approve our named executive officer compensation. NOTE: The Board of Directors will consider and act upon any other business as may properly come before the annual meeting or any adjournment or postponement thereof. For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V91729-P50928


    Get the next $CGEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGEM

    DatePrice TargetRatingAnalyst
    2/17/2026$33.00Buy
    Citigroup
    2/2/2026$30.00Buy
    Guggenheim
    8/21/2025$24.00Buy
    H.C. Wainwright
    6/11/2025$22.00Buy
    Stifel
    10/24/2024$30.00Buy
    UBS
    5/1/2024$40.00Buy
    Stifel
    4/15/2024Outperform
    William Blair
    2/15/2024$30.00Outperform
    Wedbush
    More analyst ratings

    $CGEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $1,391,686 worth of shares (165,667 units at $8.40) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/30/25 5:13:32 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $114,048 worth of shares (15,032 units at $7.59) and bought $1,989,864 worth of shares (233,717 units at $8.51) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/21/25 7:00:03 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $3,593,698 worth of shares (556,300 units at $6.46) and bought $6,233,243 worth of shares (903,341 units at $6.90) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/10/25 6:58:38 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

    New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies  Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to be shared Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biop

    5/26/26 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

    Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLN-049, a novel, investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). "FDA Orphan Drug Designation for CLN-049 emphasizes both the urgent need for n

    5/19/26 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

    CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom. The presentation will feature data from the Phase 1 OUTRACE RA and OUTRACE SLE studies which are evaluating CLN-978 in patients with

    5/18/26 5:00:00 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    SEC Filings

    View All

    Cullinan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)

    5/18/26 5:30:08 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cullinan Therapeutics Inc.

    SCHEDULE 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    5/15/26 4:05:42 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Cullinan Therapeutics Inc.

    10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)

    5/7/26 7:08:55 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Cullinan Therapeutics with a new price target

    Citigroup initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $33.00

    2/17/26 8:16:46 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Cullinan Therapeutics with a new price target

    Guggenheim initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00

    2/2/26 6:51:16 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Cullinan Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $24.00

    8/21/25 8:17:52 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Michaelson Jennifer exercised 4,000 shares at a strike of $4.30 and sold $116,996 worth of shares (8,000 units at $14.62) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 166,844 units (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    5/6/26 5:00:27 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Michaelson Jennifer sold $125,440 worth of shares (8,000 units at $15.68) and exercised 4,000 shares at a strike of $4.30, decreasing direct ownership by 2% to 170,844 units (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    3/9/26 5:00:03 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Michaelson Jennifer sold $25,169 worth of shares (1,780 units at $14.14), decreasing direct ownership by 1% to 174,844 units (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    2/26/26 5:05:13 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Leadership Updates

    Live Leadership Updates

    View All

    Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

    CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. "I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio," said Nadim Ahmed, Chief Executive Officer, Cullinan Therapeutics. "Mary Kay brings a wealth of expertise to our team with a successful track record marked by pivotal roles leading in a variety of fast

    4/29/24 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

    CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointed to the company's Board of Directors ("Board"). Dr. Ryan brings over 20 years of oncology experience and joins Cullinan Oncology from Massachusetts General Hospital ("MGH") Cancer Center where he holds the position of Clinical Director and has been the Chief of the MGH Cancer Center since 2012.   Dr. Ryan holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. Following the completion of his

    11/2/22 8:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

    CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today announced that Jacquelyn (Jackie) Sumer, J.D., will join the company as Chief Legal Officer. Jackie brings with her nearly two decades of legal and strategic leadership experience, with proven skills in navigating legal and compliance issues through clinical development and commercialization of cancer therapies. "The appointment of Jackie as Chief Legal Officer brings her exceptional expertise and legal guidance a

    8/15/22 4:57:42 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/24 5:05:22 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/24 4:24:39 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/12/24 2:23:54 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Financials

    Live finance-specific insights

    View All

    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

    Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026  Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA; PDUFA target action date of February 27, 2027 Cash and investments of $393.3 million as of March 31, 2026; runway into 2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights

    5/7/26 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its fin

    3/10/26 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D., and Andrew Allen, M.D., Ph.D., to its Board of Directors CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focu

    8/7/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care